Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient did not take the third dose of Vivotif on 05-Jul-2025; Case reference number US-BN-2025-001156 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-1630) on 07-Jul-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 01-Jul-2025 also reported as on Tuesday, the patient took the first dose of Vivotif (batch number: unknown) orally, at an unknown dose, for an unknown indication. On 03-Jul-2025 also reported as on Thursday, two days after the patient took the first dose, the patient took the second dose of Vivotif (batch number: unknown) orally, at an unknown dose. As reported, the patient forgot to take the Saturday's dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: This case concerns a male patient of unspecified age, who received first and second doses of Vivotif vaccine, for an unknown indication. As reported, patient forgot to take the third dose, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a male patient of unspecified age, who received first and second doses of Vivotif vaccine, for an unknown indication. As reported, patient forgot to take the third dose, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE